AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients

Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in...

Related Keywords

Germany ,Melbourne ,Victoria ,Australia ,Ludwigshafen ,Rheinland Pfalz ,German ,Mariana Cota Stirner ,Arnonp Kater ,John Seymour ,Othman Al Sawaf ,Venclyxto Sm ,Abbvie Deutschland Gmbh Co ,Roche Group ,Instagram ,Study Group ,European Hematology Association ,Blood Cancer Press Kit ,University Hospital Cologne ,Genentech ,Twitter ,Linkedin ,Exchange Commission ,Youtube ,Facebook ,Annual Congress ,Confidence Interval ,Hazard Ratio ,Integrated Haematology Department ,Peter Maccallum Cancer Center ,Royal Melbourne Hospital ,Cumulative Illness Rating Scale ,Crcl This ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Product Characteristics ,Abbvie Deutschland Gmbh ,